Antisoma announces positive phase 1 data, regains rights for R1550

By Elaine Rigoli

Tampa, Fla., June 5 - Antisoma plc announced the successful completion of a phase 1 trial of R1550 (huHMFG1). The safety study in patients with metastatic, or spreading, breast cancer showed that the drug was well tolerated at the maximum dose tested, clearing the way for further development in patients with less-advanced disease.

While analysis of efficacy was not a primary aim, a number of patients showed prolonged stabilization of disease, the company said in a news release.

Antisoma also said it has reached an agreement with Roche to regain all rights to R1550, which will now be redesignated AS1402.

Antisoma said it plans to move the drug rapidly into a phase 2a study in breast cancer patients awaiting surgery after initial diagnosis, and data is expected during 2007.

Based in London, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.